The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (176.23) USD. With the latest stock price at 5.52 USD, the upside of Immunitybio Inc based on DCF is -3292.6%.
Based on the latest price of 5.52 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 3292.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.4% - 7.9% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (388.41) - (116.93) | (176.23) |
| Upside | -7136.5% - -2218.3% | -3292.6% |